We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

131 hedge funds and large institutions have $652M invested in Sciclone Pharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

206% more capital invested

Capital invested by funds: $213M → $652M (+$439M)

13% more funds holding

Funds holding: 116131 (+15)

12% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

35% less call options, than puts

Call options by funds: $608K | Put options by funds: $939K

Holders
131
Holders Change
+15
Holders Change %
+12.93%
% of All Funds
3.49%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
47
Reduced
42
Closed
8
Calls
$608K
Puts
$939K
Net Calls
-$331K
Net Calls Change
-$168K

SCLN Hedge Fund Activity: Q4 2014 in Review

131 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2014, worth a combined $652M — up 206% from $213M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SCLN positions and 8 closed out — a net gain of 17 holders — while 47 added to existing stakes and 42 trimmed.

The largest buyer was McKinley Capital Management, opening a new position worth an estimated $6.86M. The largest seller was LSV Asset Management, cutting an estimated $4.19M.

  • 131 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2014, up from 116 in Q3 2014.
  • Funds reported $652M of Sciclone Pharmaceuticals Inc stock for Q4 2014, up 206% quarter-over-quarter.
  • 25 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2014 and 8 closed out, a net change of +17 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q4 2014 was McKinley Capital Management, an estimated $6.86M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q4 2014 was LSV Asset Management, an estimated $4.19M sold.

Based on aggregated 13F filings for Q4 2014.